iSERA Lifesciences Ltd vs Infosys Ltd
A side-by-side comparison of iSERA Lifesciences Ltd (534920) and Infosys Ltd (INFY) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Infosys Ltd leads 534920 vs INFY on 10 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- − ["Stock is trading at 14.7 times its book value", "Company has high debtors of 322 days.", "Promoter holding has decreased over last 3 years: -41.4%"]
- + ["Stock is providing a good dividend yield of 4.25%.", "Company has a good return on equity (ROE) track record: 3 Years ROE 30.8%", "Company has been maintaining a healthy dividend payout of 68.5%", "Company's working capital requirements have reduced from 42.0 days to 32.7 days"]
- − ["Promoter holding has decreased over last quarter: -0.56%", "Promoter holding is low: 13.8%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.